JFG
VERV

Jefferies Financial Group’s Verve Therapeutics VERV Stock Holding History

Jefferies Financial Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-177,716
Closed -$3.33M – 2014
2023
Q2 		$3.33M Sell
177,716
-89,355
-33% -$1.49M 0.03% 493
2023
Q1 		$3.85M Sell
267,071
-8,642
-3% -$169K 0.03% 439
2022
Q4 		$5.34M Buy
+275,713
New +$7.31M 0.04% 390

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Jefferies Financial Group's VERV Position: Q3 2023 in Review

Jefferies Financial Group sold out of Verve Therapeutics (VERV) in Q3 2023, closing a stake of 177,716 shares — an estimated $3.33M sold.

Jefferies Financial Group first reported a position in VERV in Q4 2022 and held it in 3 quarters. The position peaked at $5.34M in Q4 2022. 134 funds tracked by Wall St. Rank hold VERV as of Q3 2023.

  • Jefferies Financial Group reported no remaining Verve Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Jefferies Financial Group sold 177,716 Verve Therapeutics shares in Q3 2023, an estimated $3.33M.
  • Jefferies Financial Group first reported a position in Verve Therapeutics in Q4 2022 and held it in 3 quarters.
  • Jefferies Financial Group's Verve Therapeutics position peaked at $5.34M in Q4 2022.
  • 134 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2023.

Based on Jefferies Financial Group's 13F filing for Q3 2023, filed 14 Nov 2023.